ResMed Analyst Price Targets - Benzinga

ResMed Inc

RMDNYSE

Trade with Public

Trade with Public

$229.82

-1.05-0.45%

最終更新: Sep 3, 1:07 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

ResMed Analyst Price Targets

Wall Street analyst price targets and consensus rating for ResMed (RMD).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

5Buy

8Hold

1Sell

Consensus RatingNeutral# Analysts14Avg. Consensus PT$244Upside to Avg. PT+6.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 31, 2026	Keybanc	Brett Fishbin	PT Raise	Overweight	$255→$267
Aug 19, 2026	Rothschild & Co	Jackson Philips	Initiate	Neutral	$230
Aug 7, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Sector Perform	$234→$244
Aug 7, 2026	Piper Sandler	Adam Maeder	PT Cut	Neutral	$233→$225
Aug 7, 2026	Keybanc	Brett Fishbin	PT Cut	Overweight	$260→$255
Aug 7, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$225→$215
Jul 15, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$235→$220
Jul 13, 2026	Citigroup	Laura Sutcliffe	Downgrade	Buy→Neutral	$270→$235
Jul 10, 2026	Jefferies	Matthew Taylor	PT Cut	Hold	$240→$225
Jul 8, 2026	RBC Capital	Craig Wong-Pan	PT Cut	Outperform	$321→$276
Jul 8, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$227→$225
Jun 22, 2026	Keybanc	Justin Patterson	PT Cut	Overweight	$290→$266
Jun 17, 2026	Morgan Stanley	David Bailey	Downgrade	Overweight→Equal-Weight	$286→$230
Jun 15, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$340→$270
May 1, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Outperform	$314→$321
May 1, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$270→$227
Apr 27, 2026	Keybanc	Brett Fishbin	PT Cut	Overweight	$302→$290
Apr 15, 2026	JP Morgan	David Low	Reinstates	Overweight	—
Apr 9, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$345→$340
Feb 2, 2026	Citigroup	Laura Sutcliffe	PT Raise	Buy	$330→$345

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.

Benzinga Newsdesk

PRO
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.

Benzinga Newsdesk

PRO
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215

Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.

Benzinga Newsdesk